📈 Price History

Ratio Health

— Excellent

— Good

— Average

— Poor

By Category

📊 Sector Averages

About

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company’s novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFβ) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. The company is developing Apitegromab, an inhibitor of the activation of myostatin, which is in a Phase 2 clinical trial for the treatment of SMA and facioscapulohumeral muscular dystrophy (FSHD). Additionally, SRK-439, an anti-pro/latent myostatin antibody, is in a Phase 1 clinical trial for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. SRK-181 is a Phase 2-ready investigational inhibitor of latent TGFβ1 for the treatment of patients with solid tumors that are resistant to anti-PD-(L)1 antibody therapies. The company also offers products in pre-clinical development, including SRK-373, a selective inhibitor of the latent TGFβ1 isoform with selective activity in the fibrotic extracellular matrix, for the treatment of fibrotic diseases, and SRK-256, an inhibitor of RGMc, or hemojuvelin, for the treatment of iron-restricted anemias. Scholar Rock Holding Corporation is also developing a pipeline that includes programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Key Ratios Snapshot

📈 Growth Pattern

⚡ Latest Quarter —

See full financials →

📊 Quick Scorecard

Loading…

🔍 Concall Decoded

🎙 Management Tone Tracker Confident Specific → Stable 4 quarters analysed

Q2 2025

Confident Specific

Management repeatedly expressed confidence in the September 22 PDUFA date, despite CDMO observations, citing a constructive late-cycle meeting with the FDA. They detailed concrete commercial readiness (field team fully deployed, payer discussions ongoing) and pipeline milestones (OPAL trial, SRK-439 IND).

Q3 2025

Mixed

management expresses strong conviction in eventual approval ('not a matter of if, but when') and pride in Type A meeting collaboration, yet remains cautious about exact timelines and outcomes, using phrases like 'we will continue to work with urgency' and 'we await the final minutes'. No overt defensiveness, but several forward-looking statements are hedged.

Q4 2025

Confident Specific

Management used phrases like 'poised for a transformative year', 'steady and rapid progress', 'shared sense of urgency' and detailed step-by-step interactions with FDA, indicating confidence in the near-term regulatory path while acknowledging the remaining gating item of re-inspection.

Q1 2026 latest

Confident Specific

Management consistently used language like 'very pleased', 'gratified', 'significant progress', 'we are well-positioned', and reiterated readiness for immediate launch, indicating high confidence and specificity.

Guidance Reliability Pending · <3Q data

Investor Lens

The investment thesis is materially stronger after this call. The key regulatory risk has been substantially mitigated by having two independent fill-finish facilities in the BLA, with commercial supply from the second facility expected well before the PDUFA date. The probability of a U.S. approval by September 30, 2026, has increased significantly. Additionally, commercial readiness appears advanced, and early European progress (CHMP opinion near mid-year) adds optionality. Key catalysts to watch include the FDA's classification of Catalent Indiana within 90 days, any early approval action, and the CHMP opinion. The absence of pricing or revenue guidance is not surprising pre-launch. Overall, the thesis is stronger with reduced regulatory overhang and clear near-term milestones.

AI-generated concall tone analysis · Updated 2026-06-08 · Not investment advice

🎙 Management Tone Confident Specific → Stable 4 quarters Full tone analysis in Intelligence →

📊 MIXED FDA accepts apitegromab BLA; PDUFA Sept 30, 2026; $480M cash

Revenue & Profitability

For Q1 2026, Scholar Rock reported total operating expenses of $102 million, including $80 million in non-cash stock-based compensation. Excluding stock-based compensation, operating expenses were $84 million. The company ended the quarter with $480 million in cash, cash equivalents, and marketable securities. It drew $100 million from its debt facility in March and raised $98 million net from its ATM program. No revenue was reported.

Outlook

Management expects approval of apitegromab in the U.S. by the PDUFA date (September 30, 2026) and a CHMP opinion in Europe near mid-2025. They anticipate significant unmet need in SMA, noting that 95% of patients on SMN-targeted therapies still experience muscle atrophy. In FSHD, there are no approved therapies, and the company sees a large addressable market of over 30,000 diagnosed patients in the U.S. and Europe.

Growth Drivers

Key growth drivers include the global launch of apitegromab for SMA, with the U.S. launch expected upon FDA approval and a European launch (starting in Germany) anticipated by mid-2025. The Phase II FORGE study in FSHD is expected to begin enrollment in mid-2025. Additional pipeline programs include a subcutaneous formulation of apitegromab and SRK-439, which are expected to expand the company's addressable patient population.

Balance Sheet & CapEx

Not discussed in this earnings call.

Margins

Not discussed in this earnings call.

Key Risks

Key risks include the FDA's classification of the Catalent Indiana fill-finish facility, which could affect approval timing. The company also faces risks related to manufacturing, regulatory delays, and competition. Analysts questioned the impact of the Roche/Chugai FSHD discontinuation and the potential for label breadth in SMA. Management acknowledged the reliance on two facilities for approval.

Generated by AI · Q1 2026 results · Not investment advice

✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter

🔍

🔎 See cross-company document search → ?

📞 Earnings Call Transcripts (5)

Q2 2026 Q2 2026 2026-08-06

Apitegromab is on track for FDA approval by September 30, 2026, with robust commercial and financial readiness and two independent manufacturing paths mitigating regulatory risk. European launch preparations are advancing, and the anti-myostatin pipeline shows strong progress.

Q1 2026 Q1 2026 2026-05-07

FDA accepted the BLA for apitegromab with two fill-finish facilities, setting a PDUFA date of September 30, 2026. Commercial and regulatory preparations are advanced in the U.S. and Europe, with $480 million in liquidity and a robust pipeline supporting future growth.

Q4 2025 Q4 2025 2026-03-03

Poised for a transformative 2026, the company is advancing regulatory filings and commercial readiness for apitegromab in SMA, with strong financial backing and pipeline progress. Regulatory and supply chain risks are being actively managed, and robust market demand is anticipated.

Q3 2025 Q3 2025 2025-11-14

Apitegromab's U.S. approval was delayed due to manufacturing compliance, not efficacy or safety. The company is expediting remediation with Novo Nordisk and adding a second fill-finish facility, aiming for a 2026 launch. Cash reserves are strong, supporting operations into 2027.

Q2 2025 Q2 2025 2025-08-06

Apitegromab is on track for U.S. launch in Q3 2025 pending FDA approval, with European expansion planned for 2026. Financial position is strong with a cash runway into 2027, and commercial teams are fully prepared. Regulatory and manufacturing risks are being actively managed.

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯

Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.

📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.